Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
No analyst coverage available for this stock.
Trend
+18.9% vs SMA 50 · +72.6% vs SMA 200
Momentum
Volume distribution is neutral or leaning toward distribution. No compelling squeeze setup based on current money flow data.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
INSTITUTIONAL OWNERSHIP
PTGX News
Unable to load news
About
Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a 150 patient Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional second-generation oral interleukin-23 receptor antagonist candidates PN-235 and PN-232, are in early stages of clinical development. The Company has developed a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
PTGX◀ | $99.50 | -0.61% | $6.3B | — | -8940.8% | -28283.4% | 1500 |
| $68.91 | -3.59% | $13.3B | — | +12626.1% | -14525.8% | 1500 | |
| $520.84 | -0.71% | $11.8B | — | +43205.3% | -3008.0% | 1500 | |
| $88.52 | +0.60% | $11.5B | — | +3288.2% | -4239.0% | 1500 | |
| $181.75 | -1.59% | $10.7B | 29.2 | +1871.5% | 680.1% | 1500 | |
| $228.45 | -0.59% | $10.6B | — | +6554.5% | -2868.8% | 1500 | |
| $75.32 | +1.81% | $10.5B | 51.8 | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -0.67% | — | 40.5 | +340631.4% | -7466.4% | 1500 |